Valuation
- Market cap
- 708,000
- Revenue TTM
- $21,480,000
- Net income TTM
- $-79,460,000
- PE ratio
- 0.00
- Forward PE
- —
- Profit margin
- -369.93%
- Debt to equity
- 0.00
Trading
- Volume
- 10,600
- Avg volume
- 26,130
- Day's range
- $0.01 – $0.02
- Shares out
- 29,491,000
- Stochastic %K
- 100%
- Beta
- 0.38
- Analysts
- Strong Buy
- Price target
- $22.00
Company profile
SQZ Biotechnologies Company, a clinical-stage biotechnology company, develops cell therapies for patients with cancer, infectious diseases, and other serious conditions in Massachusetts. Its lead product candidate is SQZ-PBMC-HPV, from its SQZ Antigen Presenting Cells platform, which is in a Phase I clinical trial as a monotherapy and in combination with immuno-oncology agents for the treatment of HPV16+ advanced or...
Show more
SQZ Biotechnologies Company, a clinical-stage biotechnology company, develops cell therapies for patients with cancer, infectious diseases, and other serious conditions in Massachusetts. Its lead product candidate is SQZ-PBMC-HPV, from its SQZ Antigen Presenting Cells platform, which is in a Phase I clinical trial as a monotherapy and in combination with immuno-oncology agents for the treatment of HPV16+ advanced or metastatic solid tumors, including cervical, head-and-neck, anal, penile, vulvar, and vaginal cancer. The company also develops SQZ-AAC-HPV and SQZ-eAPC-HPV, which is in a Phase I clinical trial for the treatment of HPV16+ advanced or metastatic solid tumors in monotherapy and in combinations with immune-oncology agents. Its additional platforms in development are SQZ Activating Antigen Carriers; and SQZ Tolerizing Antigen Carriers. The Company was incorporated in 2013 and is headquartered in Watertown, Massachusetts.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 617 758 8672
- Website
- https://www.sqzbiotech.com
- Address
- 200 Arsenal Yards Boulevard, Suite 210, Watertown, United States
Latest news
No headlines yet.